NORTH AMERICAN VACCINE's ACELLULAR PERTUSSIS COMPONENT IS 71% EFFECTIVE
Executive Summary
NORTH AMERICAN VACCINE's ACELLULAR PERTUSSIS COMPONENT IS 71% EFFECTIVE against whooping cough in infants, according to a National Institute of Child Health & Human Development-sponsored Phase III randomized, double-blind placebo controlled trial, the institute announced Nov. 22. Conducted at the University of Goteborg in Sweden by co-principal investigators John Taranger and Birger Trollfors, the three-year trial tested the North American Vaccine-manufactured acellular pertussis vaccine (consisting solely of a detoxified pertussis toxin), which the company compounded as DTaP using diphtheria and tetanus toxoids manufactured by the Statens Semminstitut, Copenhagen.